Paper36914702
Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.
Elanany MA and 3 others. Sci Rep, 2023. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis. Papers, record 36914702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36914702
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fluoroquinolones | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Molecular Structure | |
| Structure-Activity Relationship | |
| Moxifloxacin | |
| Cell Proliferation | |
| Cell Cycle Checkpoints | |
| Cell Line, Tumor | |
| Ciprofloxacin | |
| Apoptosis | |
| Ofloxacin | |
| Drug Screening Assays, Antitumor | |
| Cell Cycle |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34419964 | Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1. | Anticancer Drugs | 2022 | https://conductscience.org/library/papers/34419964 | PubMed |
| 2 | 2041050 | Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. | J Natl Cancer Inst | 1991 | https://conductscience.org/library/papers/2041050 | PubMed |
| 3 | 11990855 | DNA and its associated processes as targets for cancer therapy. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/11990855 | PubMed |
| 4 | 61966 | Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. | J Cell Biol | 1976 | https://conductscience.org/library/papers/61966 | PubMed |
| 5 | 30528372 | Moxifloxacin as an inducer of apoptosis in melanoma cells: A study at the cellular and molecular level. | Toxicol In Vitro | 2019 | https://conductscience.org/library/papers/30528372 | PubMed |
| 6 | 24220853 | A high-throughput image-based screen for the identification of Bax/Bak-independent caspase activators against drug-resistant cancer cells. | Apoptosis | 2014 | https://conductscience.org/library/papers/24220853 | PubMed |
| 7 | 16990858 | The NCI60 human tumour cell line anticancer drug screen. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16990858 | PubMed |
| 8 | 34016969 | Structural basis for allosteric regulation of Human Topoisomerase IIα. | Nat Commun | 2021 | https://conductscience.org/library/papers/34016969 | PubMed |
| 9 | 9176486 | The proto-oncogene Bcl-2 and its role in regulating apoptosis. | Nat Med | 1997 | https://conductscience.org/library/papers/9176486 | PubMed |
| 10 | 6266278 | "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. | Anal Biochem | 1981 | https://conductscience.org/library/papers/6266278 | PubMed |
| 11 | 22425922 | Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. | J Thorac Oncol | 2012 | https://conductscience.org/library/papers/22425922 | PubMed |
| 12 | 9794033 | Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. | Q Rev Biophys | 1998 | https://conductscience.org/library/papers/9794033 | PubMed |
| 13 | 28802125 | Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies. | Eur J Med Chem | 2017 | https://conductscience.org/library/papers/28802125 | PubMed |
| 14 | 26902121 | Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. | Biochem Biophys Res Commun | 2016 | https://conductscience.org/library/papers/26902121 | PubMed |
| 15 | 16101488 | Etoposide, topoisomerase II and cancer. | Curr Med Chem Anticancer Agents | 2005 | https://conductscience.org/library/papers/16101488 | PubMed |
| 16 | 9737386 | Experience with the Vero cell line. | Dev Biol Stand | 1998 | https://conductscience.org/library/papers/9737386 | PubMed |
| 17 | 9205852 | Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. | Drugs Aging | 1997 | https://conductscience.org/library/papers/9205852 | PubMed |
| 18 | 8953102 | Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. | Clin Infect Dis | 1996 | https://conductscience.org/library/papers/8953102 | PubMed |
| 19 | 30339990 | Synthesis, theoretical, spectroscopic and electrochemical DNA binding investigations of 1, 3, 4-thiadiazole derivatives of ibuprofen and ciprofloxacin: Cancer cell line studies. | J Photochem Photobiol B | 2018 | https://conductscience.org/library/papers/30339990 | PubMed |
| 20 | 32975138 | DNA topoisomerases as molecular targets for anticancer drugs. | J Enzyme Inhib Med Chem | 2020 | https://conductscience.org/library/papers/32975138 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793155 | Novel Lomefloxacin-Triazole Hybrids: Design, Synthesis and In Vitro Antiproliferative Activity in Breast, Melanoma and Colon Cancer Cell Lines. | Biomolecules | 2026 | https://conductscience.org/library/papers/42793155 | PubMed |
| 42660817 | Quinoline-Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances. | ChemMedChem | 2026 | https://conductscience.org/library/papers/42660817 | PubMed |
| 42197495 | Fluoroquinolone-Induced Metabolic Dysregulation and Oxidative Stress Orchestrate Bacterial Demise. | Microorganisms | 2026 | https://conductscience.org/library/papers/42197495 | PubMed |
| 41977249 | Design, Synthesis, and Bioevaluation of Moxifloxacin Hydrazide Metal Complexes: Integrated Spectroscopic, Computational, Antimicrobial, and Anticancer Investigations. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977249 | PubMed |
| 41888388 | Topoisomerase I/II inhibitors: from established drugs to next-generation therapeutics. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/41888388 | PubMed |
| 41510714 | Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024. | Mini Rev Med Chem | 2026 | https://conductscience.org/library/papers/41510714 | PubMed |
| 40469234 | Vistas in the domain of 3-acetyl-4-hydroxy-2-quinolinone derivatives (AHQ) and their applications. | RSC Adv | 2025 | https://conductscience.org/library/papers/40469234 | PubMed |
| 40430482 | Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430482 | PubMed |
| 39770435 | In Silico Evaluation of Some Computer-Designed Fluoroquinolone-Glutamic Acid Hybrids as Potential Topoisomerase II Inhibitors with Anti-Cancer Effect. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39770435 | PubMed |
| 39569131 | Drug repurposing of fluoroquinolones as anticancer agents in 2023. | RSC Adv | 2024 | https://conductscience.org/library/papers/39569131 | PubMed |
| 39191818 | Evaluating larvicidal, ovicidal and growth inhibiting activity of five medicinal plant extracts on Culex pipiens (Diptera: Culicidae), the West Nile virus vector. | Sci Rep | 2024 | https://conductscience.org/library/papers/39191818 | PubMed |
| 38486053 | Larvicidal activity of Acacia nilotica extracts against Culex pipiens and their suggested mode of action by molecular simulation docking. | Sci Rep | 2024 | https://conductscience.org/library/papers/38486053 | PubMed |
| 38357952 | Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents. | Curr Top Med Chem | 2024 | https://conductscience.org/library/papers/38357952 | PubMed |
| 38038012 | Overview of the New Bioactive Heterocycles as Targeting Topoisomerase Inhibitors Useful Against Colon Cancer. | Anticancer Agents Med Chem | 2024 | https://conductscience.org/library/papers/38038012 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36914702
GET https://conductscience.org/api/papers/v1/36914702/references?page=2